| Huntington's disease(HD)is a fatal neurodegenerative disorder characterized by progressive movement disorders and cognitive deficits,which is caused by a CAG-repeat expansion encoding an extended polyglutamine(polyQ)tract in the huntingtin protein(HTT).Reduction of mutant HTT levels and inhibition of neuroinflammation has been proposed as a major therapeutic strategy in treating HD.Intravenous immunoglob?lin(IVIg)therapy has been firmly established for the treatment of several autoimmune or inflammatory neurological diseases,either as adjunctive treatment or as first-line therapy.However,whether IVIg has therapeutic potential on HD remains unclear.Here,we firstly demonstrated that IVIg treatment rescued motor and cognitive deficits,lowered mutant HTT levels,prevented synaptic degeneration,attenuated neuroinflammation and oxidative stress in R6/2 mouse model,suggesting that IVIg is a promising therapeutic potential for HD. |
PDF Full Text Request